目的：采用Meta分析评估miR-17-92簇高表达在肿瘤患者预后中的价值。方法：检索Web of Science、PubMed、EMBASE数据库从建库至2015年10月1日关于miR-17-92簇成员高表达与恶性肿瘤患者预后关系的英文文献，提取关键数据,计算合并风险比(hazard ratio，HR)及其95%置信区间(confidence interval,CI)。结果：共纳入39篇文献,包含4 908例患者。miR-17-92簇的高表达与恶性肿瘤患者总生存率 (HR=1.83,95%CI: 1.58~2.12,P=0.000)低有关，并且miR-17-92簇高表达的肿瘤患者的无病生存率(HR=1.80 ,95% CI:1.43~2.26,P=0.000)、无进展生存率(HR=1.83,95%CI:1.11~302,P=0.018)及肿瘤特异性生存率(HR=1.59，95%CI:1.04~2.42,P=0.032)均降低；然而无复发生存率的合并风险比无统计学意义(P=0.539)。结论：miR-17-92簇高表达与恶性肿瘤患者的不良预后有关，有望成为新型肿瘤预后标志物。

Objective:Value of high-expression of miR-17-92 cluster in evaluating prognosis of cancer patients was analyzed with Meta-analysis. Methods: English literatures on the relationship of high-expression of miR-17-92 cluster and the prognosis of cancer patients were retrieved from Web of Science, PubMed and EMBASE from construction of the data bases to Oct 1, 2015. Key data were extracted from the literatures, pooled hazard ratios (HRs) and corresponding 95% confidence interval (CI) were calculated. Results: Total of thirty-nine literatures was included, involving 4 908 patients. The high-expression of miR-17-92 cluster was associated with low overall survival rate of the patients with malignant tumor (HR=1.83, 95% CI: 1.58~2.12, P=0.000). Furthermore, disease-free survival rate (HR=1.80, 95% CI: 1.43~2.26, P=0.000), progression-free survival rate (HR=1.83, 95%CI: 1.11~3.02, P=0.018) and cancer-specific survival rate (HR=1.59, 95%CI: 1.04~2.42, P=0.032) in the cancer patients with high-expression of miR-17-92 cluster were all reduced. However, the pooled HRs for relapse- free survival rate was not statistically significant (P=0539). Conclusion: The high-expression of miR-17-92 cluster was associated with poor prognosis of the patients with malignant tumor, and it could be expected as a new marker for prognosis of the cancer patients.

国家自然科学基金资助项目(No. 81273814)；广东省重大新药创制重大科技专项资助(No. 2013A022100031)